DOI: 10.1161/circulationaha.125.078536 ISSN: 0009-7322

Left Ventricular Hypertrabeculation and Prognosis in Dilated Cardiomyopathy

Nerea Mora-Ayestarán, Noemi Ramos-Lopez, Juan Pablo Ochoa, Amaia Yuan Ibargoyen, Eduard Claver-Garrido, Cristina Gómez-González, Ahmad S. Amin, María Gallego-Delgado, Guillem Casas-Masnou, Marina Navarro-Peñalver, Jose María Larrañaga-Moreira, José Manuel García-Pinilla, Francisco J. Bermudez-Jimenez, Maria Victoria Mogollón-Jiménez, Gonzalo Cabezón-Villalba, Antoni Bayes-Genis, Vicente Climent-Payá, Rafael Salguero-Bodes, Ana García-Álvarez, María Brion, Ramon Brugada, Esther Zorio, Tomas Ripoll-Vera, María Luisa Peña-Peña, Ana Royuela, Miriam Sánchez, Carles Diez-Lopez, Elena Rodríguez González, Edwin Poel, Eduardo Villacorta, Javier Limeres-Freire, María Sabater-Molina, Roberto Barriales-Villa, Gemma Lacuey-Lecumberri, Andrea Di Marco, María Angeles Espinosa-Castro, Connie R. Bezzina, José F. Rodríguez-Palomares, María Teresa Basurte-Elorz, Jesus G. Mirelis, Pablo Garcia-Pavia
Show PDF Cite

BACKGROUND:

Left ventricular (LV) hypertrabeculation, formerly termed LV noncompaction, is a heterogeneous myocardial entity linked to adverse cardiovascular outcomes. This study evaluated embolic risk in patients with dilated cardiomyopathy (DCM) according to the presence of hypertrabeculation and examined its prevalence and prognostic relevance across DCM genotypes.

METHODS:

Clinical data from 1160 patients with DCM evaluated by cardiac magnetic resonance imaging and genetic testing (n=997 [86%]) were collected from 22 international centers. End points included embolic events, advanced heart failure events, and major ventricular arrhythmias.

RESULTS:

LV hypertrabeculation was identified in 354 patients (30.5%) by fractal analysis and in 343 (29.7%) according to Petersen criteria, with good concordance. After a median follow-up of 5.1 years (interquartile range, 2.8–7.4), embolic events occurred in 37 patients (3.2%), advanced heart failure in 62 (5.3%), and major ventricular arrhythmias in 136 (11.7%). Hypertrabeculation was not associated with increased embolic risk (hazard ratio, 1.5 [95% CI, 0.75–3.00]), even among patients in sinus rhythm with LV ejection fraction ≤40% (hazard ratio, 1.89 [95% CI, 0.7–5.5]). In contrast, atrial fibrillation and reduced LV ejection fraction were associated with embolic events (both P <0.01). LV hypertrabeculation was not associated with an increased risk of major ventricular arrhythmias or advanced heart failure; genotype, LV ejection fraction, and late gadolinium enhancement emerged as the main predictors of adverse outcomes. The prevalence of LV hypertrabeculation varied across genotypes, with the highest prevalence observed in patients with sequence variants in motor sarcomeric genes (58%), TTN (38%), and genotype-negative status (33%), and the lowest prevalence observed among those with variants in cytoskeletal/Z-disk (7%) and nuclear envelope (5%) genes. Hypertrabeculation was not associated with adverse outcomes within any genotype.

CONCLUSIONS:

Although LV hypertrabeculation is common in DCM, it is not associated with worse outcomes and should not prompt differential clinical management. The embolic risk in patients with DCM and hypertrabeculation is low, including in those with reduced LV ejection fraction without atrial fibrillation, and does not support prophylactic anticoagulation in these patients.

More from our Archive